This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Chapter 9: Insulin treatment in children and adolescents with diabetes

Chapter 9: Insulin treatment in children and adolescents with diabetes

Thomas Danne,  Moshe Phillip, Bruce Buckingham, Przemyslawa Jarosz-Chobot, Banshi Saboo, Tatsuhiko Urakami, Tadej Battelino, Ragnar Hanas and Ethel Codner 

The 2018 ISPAD Clinical Practice Consensus Guidelines on Insulin treatment describes how insulin remains at the core of all recent advances in the treatment of children with diabetes.

The chapter details how to use traditional insulins and new insulin analogs appropriately in each individual based on factors including: age, duration of diabetes, lifestyle (dietary patterns, exercise schedules, school, work commitments etc.), targets of metabolic control and particularly individual patient/family preferences.

It summarizes current pediatric recommendations for insulin injection and of devices for insulin delivery. It gives updated advice for pediatric insulin dose adjustments and guidance on approaches for persistent deviations of glucose levels from target

The guideline reviews the evidence of how the traditional insulins have certain clinical limitations and how the development of new analogs, rapid and long-acting, have resulted in some improvement in the care of diabetes, but that their beneficial extent in a long-term clinical setting is not fully established.

The chapter points out that biosimilars might lower the price for insulin, make it more accessible and affordable for many pediatric patients but bioequivalence has to be established through proper clinical trials and pharmacovigilance with reporting of any side effects observed.

It confirms that the currently available data continues to show the safety of insulin analogs for pediatric use.

Contact Us

ISPAD Executive Office
c/o K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin, Germany


Click the link below to join the Society!

Join Today!

Phone: +49 (0)30 24603-210
Fax: +49 (0)30 24603-200
Email: secretariat@ispad.or

Privacy Policy
Terms of Service
Legal Notice    


 © 2020 International Society for Pediatric and Adolescent Diabetes (ISPAD)

Association Management Software Powered by YourMembership  ::  Legal